Sutro Biopharma, Inc. (S09.F)
| Previous Close | 4.3200 |
| Open | 4.2800 |
| Bid | 4.2800 x 0 |
| Ask | 4.4200 x 0 |
| Day's Range | 4.2800 - 4.2800 |
| 52 Week Range | 3.2000 - 8.0500 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 250.608M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8200 |
| Earnings Date | Mar 07, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.71 |
- GlobeNewswire
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors (i) granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units (RSUs) of Sutro common stock in connection with her a
- Simply Wall St.
Sutro Biopharma, Inc. (NASDAQ:STRO) insider upped their holding by 4.3% earlier this year
Looking at Sutro Biopharma, Inc.'s ( NASDAQ:STRO ) insider transactions over the last year, we can see that insiders...
- GlobeNewswire
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in an Ovarian Cancer panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET / 6:10 a.m. PT in Boston, MA. The presentation will be acce
